PMID- 34337965
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 1943-569X (Electronic)
IS  - 0003-1488 (Linking)
VI  - 259
IP  - 4
DP  - 2021 Aug 15
TI  - A prospective, randomized, placebo-controlled, double-blinded clinical trial 
      comparing the incidence and severity of gastrointestinal adverse events in dogs 
      with cancer treated with piroxicam alone or in combination with omeprazole or 
      famotidine.
PG  - 385-391
LID - 10.2460/javma.259.4.385 [doi]
AB  - OBJECTIVE: To assess the impact of prophylactic omeprazole and famotidine on the 
      incidence and severity of gastrointestinal (GI) adverse events (AEs) in dogs with 
      cancer treated with single agent piroxicam. ANIMALS: 39 dogs with a cytologic or 
      histologic diagnosis of cancer with no history of GI disease and received 
      piroxicam. PROCEDURES: A prospective, randomized, placebo-controlled, 
      double-blinded clinical trial was performed. All dogs received piroxicam (0.3 
      mg/kg [0.14 mg/lb], PO, q 24 h) and either omeprazole (1 mg/kg [0.45 mg/lb], PO, 
      q 12 h), famotidine (1 mg/kg, PO, q 12 h), or placebo (lactose; PO, q 12 h). 
      Monthly assessments of GI AEs were performed and scored by using the Veterinary 
      Comparative Oncology Group's Common Terminology Criteria for Adverse Events 
      (version 1.1). RESULTS: Compared with dogs in the placebo group, more dogs in the 
      omeprazole group (84.6% vs 36.4%) and famotidine group (80.0% vs 36.4%) 
      experienced GI AEs by day 56. The severity of GI AEs was higher in the omeprazole 
      group, compared with the placebo group. CONCLUSIONS AND CLINICAL RELEVANCE: 
      Omeprazole was not helpful in reducing the frequency or severity of GI AEs and 
      was associated with more frequent and severer GI AEs in dogs with cancer treated 
      with single agent piroxicam. Proton-pump inhibitors and H2-receptor antagonists 
      should not be prescribed as prophylaxis with NSAIDs for dogs with cancer.
FAU - Shaevitz, Marejka H
AU  - Shaevitz MH
FAU - Moore, George E
AU  - Moore GE
FAU - Fulkerson, Christopher M
AU  - Fulkerson CM
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial, Veterinary
PL  - United States
TA  - J Am Vet Med Assoc
JT  - Journal of the American Veterinary Medical Association
JID - 7503067
RN  - 13T4O6VMAM (Piroxicam)
RN  - 5QZO15J2Z8 (Famotidine)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - Animals
MH  - *Dog Diseases/chemically induced/drug therapy/epidemiology
MH  - Dogs
MH  - Famotidine/adverse effects
MH  - Incidence
MH  - *Neoplasms/veterinary
MH  - Omeprazole/adverse effects
MH  - Piroxicam/adverse effects
MH  - Prospective Studies
EDAT- 2021/08/03 06:00
MHDA- 2021/08/05 06:00
CRDT- 2021/08/02 08:42
PHST- 2021/08/02 08:42 [entrez]
PHST- 2021/08/03 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
AID - 10.2460/javma.259.4.385 [doi]
PST - ppublish
SO  - J Am Vet Med Assoc. 2021 Aug 15;259(4):385-391. doi: 10.2460/javma.259.4.385.